<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00014625</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-16005-18002</org_study_id>
    <secondary_id>EORTC-16005</secondary_id>
    <secondary_id>EORTC-18002</secondary_id>
    <secondary_id>EISAI-E7070-E044-205</secondary_id>
    <nct_id>NCT00014625</nct_id>
  </id_info>
  <brief_title>E7070 in Treating Patients With Stage IV Melanoma</brief_title>
  <official_title>Open Label Phase II Study Of E7070 In Patients With Metastatic Melanoma (Stage IV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die.

      PURPOSE: Phase II trial to study the effectiveness of E7070 in treating patients who have
      stage IV melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the therapeutic activity of E7070 in terms of objective response,
      duration of response, and progression-free survival of patients with metastatic melanoma. II.
      Determine the acute side effects of this drug in these patients. III. Determine the
      pharmacokinetic parameters of this drug in these patients.

      OUTLINE: This is a multicenter study. Patients receive E7070 IV over 1 hour. Treatment
      repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
      Patients are followed every 6 weeks.

      PROJECTED ACCRUAL: A total of 19-24 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <primary_completion_date type="Actual">November 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">28</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indisulam</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed stage IV melanoma Metastatic disease At
        least 1 bidimensionally measurable target lesion by CT scan No brain metastases

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 OR WHO 0-2 Life
        expectancy: Not specified Hematopoietic: Hemoglobin greater than 10 g/dL Neutrophil count
        greater than 2,000/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin less than
        1.5 times upper limit of normal (ULN) Alkaline phosphatase no greater than 2.5 times ULN (5
        times ULN if liver metastases present) Transaminases no greater than 2.5 times ULN (5 times
        ULN if liver metastases present) Renal: Creatinine no greater than 1.7 mg/dL
        Cardiovascular: Clinically normal cardiac function No history of severe or unstable
        ischemic heart disease 12-lead ECG normal Other: No history of unstable systemic disease No
        concurrent uncontrolled diabetes mellitus No concurrent infection No history of
        hypersensitivity to sulfonamides No other malignancy within the past 5 years except
        cone-biopsied carcinoma of the cervix or adequately treated basal cell or squamous cell
        skin cancer No psychological, familial, sociological, or geographical condition that would
        preclude study Not pregnant or nursing Negative pregnancy test Fertile patients must use
        effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 2 weeks since prior blood transfusions
        At least 2 weeks since prior growth factors At least 6 weeks since prior experimental
        vaccine therapy No prior immunotherapy for metastatic disease No concurrent anticancer
        immunotherapy Chemotherapy: No prior chemotherapy for metastatic disease No other
        concurrent anticancer chemotherapy Endocrine therapy: No concurrent anticancer hormonal
        therapy Radiotherapy: No concurrent anticancer radiotherapy except palliation for pain
        control or other reasons (e.g., bronchial obstruction or ulcerating skin lesions) with no
        curative intent Surgery: Not specified Other: At least 6 weeks since prior adjuvant or
        neoadjuvant therapy At least 4 weeks since prior experimental drugs At least 2 weeks since
        prior and no concurrent coumarin anti-coagulants, terfenadine, cisapride, cyclosporine,
        tacrolimus, theophylline, diazepam, sulfonylurea anti-diabetics, phenytoin, or
        carbamazepine No other concurrent experimental agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John F. Smyth, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Edinburgh Cancer Centre at Western General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steinar Aamdal, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Norwegian Radium Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Franz Josef Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>A-1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35064</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwegian Radium Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N-0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues de Oncologia de Francisco Gentil</name>
      <address>
        <city>Lisbon</city>
        <zip>1093</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Smyth JF, Aamdal S, Awada A, Dittrich C, Caponigro F, Sch√∂ffski P, Gore M, Lesimple T, Djurasinovic N, Baron B, Ravic M, Fumoleau P, Punt CJ; EORTC New Drug Development and Melanoma Groups. Phase II study of E7070 in patients with metastatic melanoma. Ann Oncol. 2005 Jan;16(1):158-61.</citation>
    <PMID>15598954</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2001</study_first_submitted>
  <study_first_submitted_qc>February 13, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2004</study_first_posted>
  <last_update_submitted>July 23, 2012</last_update_submitted>
  <last_update_submitted_qc>July 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

